MARKET

TRML

TRML

Tourmaline Bio
NASDAQ
15.39
+0.85
+5.85%
Pre Market: 14.99 -0.4 -2.60% 04:10 05/08 EDT
OPEN
14.43
PREV CLOSE
14.54
HIGH
15.51
LOW
13.63
VOLUME
100
TURNOVER
--
52 WEEK HIGH
29.79
52 WEEK LOW
11.56
MARKET CAP
395.35M
P/E (TTM)
-4.7813
1D
5D
1M
3M
1Y
5Y
1D
Tourmaline Bio’s Promising Clinical Developments and Strategic Expansion Drive Buy Rating
TipRanks · 1d ago
Tourmaline Bio Reports Q1 2025 Financial Results
TipRanks · 1d ago
Weekly Report: what happened at TRML last week (0428-0502)?
Weekly Report · 2d ago
Analysts Are Bullish on These Healthcare Stocks: Tourmaline Bio (TRML), Tvardi Therapeutics (TVRD)
TipRanks · 2d ago
Tourmaline Bio Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
Tourmaline Bio Is Maintained at Buy by Chardan Capital
Dow Jones · 2d ago
Tourmaline Bio Price Target Maintained With a $70.00/Share by Chardan Capital
Dow Jones · 2d ago
Chardan Capital Maintains Buy on Tourmaline Bio, Maintains $70 Price Target
Benzinga · 2d ago
More
About TRML
More
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company. The Company is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. The Company’s initial product candidate is pacibekitug (TOUR006), a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. It is focused on two strategic paths for TOUR006, the first of which is cardiovascular inflammation. Its second strategic path is thyroid eye disease (TED). TED is an autoimmune disease characterized by autoantibody-mediated activation of the tissues surrounding the eye, causing inflammation and disfigurement which can be sight-threatening in severe cases.
Recently
Symbol
Price
%Change

Webull offers Tourmaline Bio Inc stock information, including NASDAQ: TRML real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRML stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRML stock methods without spending real money on the virtual paper trading platform.